Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial
In a randomized trial, Sanjeev Krishna and colleagues test for non-inferiority of a simplified artemisinin regimen as treatment for malaria in a low-resource setting.
Vyšlo v časopise:
Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial. PLoS Med 13(1): e32767. doi:10.1371/journal.pmed.1001938
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001938
Souhrn
In a randomized trial, Sanjeev Krishna and colleagues test for non-inferiority of a simplified artemisinin regimen as treatment for malaria in a low-resource setting.
Zdroje
1. Kremsner PG, Taylor T, Issifou S, Kombila M, Chimalizeni Y, Kawaza K, et al. A simplified intravenous artesunate regimen for severe malaria. J Infect Dis. 2012;205:312–319. doi: 10.1093/infdis/jir724 22180622
2. World Health Organization. Guidelines for the treatment of malaria. Geneva: World Health Organization; 2015.
3. Krishna S, Planche T, Agbenyega T, Woodrow C, Agranoff D, Bedu-Addo G, et al. Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrob Agents Chemother. 2001;45:509–516. 11158748
4. Nealon C, Dzeing A, Muller-Romer U, Planche T, Sinou V, Kombila M, et al. Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother. 2002;46:3933–3939. 12435698
5. Dondorp AM, Maude RJ, Hendriksen IC, Day NP, White NJ. Artesunate dosing in severe falciparum malaria. J Infect Dis. 2012;206:618–619. doi: 10.1093/infdis/jis389 22732917
6. Kremsner PG, Taylor T, Issifou S, Kombila M, Chimalizeni Y, Kawaza K, et al. A simplified intravenous artesunate regimen for severe malaria—reply. J Infect Dis. 2012;206:621–622.
7. Kremsner PG, Valim C, Missinou MA, Olola C, Krishna S, Issifou S, et al. Prognostic value of circulating pigmented cells in African children with malaria. J Infect Dis. 2009;199:142–150. doi: 10.1086/595295 19086817
8. Taylor T, Olola C, Valim C, Agbenyega T, Kremsner P, Krishna S, et al. Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg. 2006;100:615–622. 16551469
9. World Health Organization. Management of severe malaria: a practical handbook—3rd ed. Available: http://apps.who.int/iris/bitstream/10665/79317/1/9789241548526_eng.pdf. Accessed 3 December 2015.
10. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Chanthavanich P, Bunnag D, et al. Quinine loading dose in cerebral malaria. Am J Trop Med Hyg. 1983;32:1–5.
11. Karunajeewa HA, Reeder J, Lorry K, Dabod E, Hamzah J, Page-Sharp M, et al. Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea. Antimicrob Agents Chemother. 2006;50:968–974. 16495259
12. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, Bierman WF, Clerinx J, van Veldhuizen CK, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J. 2012;11:102. doi: 10.1186/1475-2875-11-102 22462806
13. Rolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard GD, Cramer JP. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar J. 2012;11:169. doi: 10.1186/1475-2875-11-169 22594446
14. Rolling T, Wichmann D, Schmiedel S, Burchard GD, Kluge S, Cramer JP. Artesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis. Malar J. 2013;12:241. doi: 10.1186/1475-2875-12-241 23855745
15. Centers for Disease Control and Prevention. Published reports of delayed hemolytic anemia after treatment with artesunate for severe malaria—worldwide, 2010–2012. MMWR Morb Mortal Wkly Rep. 2013;62:5–8. 23302816
16. Rolling T, Agbenyega T, Issifou S, Adegnika AA, Sylverken J, Spahlinger D, et al. Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria—a double-center prospective study. J Infect Dis. 2014;209:1921–1928. doi: 10.1093/infdis/jit841 24376273
17. World Health Organization Communicable Diseases Cluster. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94 (Suppl 1):S1–S90. 11103309
18. Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8:e1001119. doi: 10.1371/journal.pmed.1001119 22087077
19. Planche T, Krishna S, Kombila M, Engel K, Faucher JF, Ngou-Milama E, et al. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg. 2001;65:599–602. 11716121
20. Geditz MC, Heinkele G, Ahmed A, Kremsner PG, Kerb R, Schwab M, et al. LC-MS/MS method for the simultaneous quantification of artesunate and its metabolites dihydroartemisinin and dihydroartemisinin glucuronide in human plasma. Anal Bioanal Chem. 2014;406:4299–4308. doi: 10.1007/s00216-014-7820-x 24760398
21. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–55. doi: 10.1038/nature12876 24352242
22. Wellek S. Testing statistical hypotheses of equivalence and noninferiority. 2nd ed. London: Chapman and Hall/CRC; 2010.
23. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med. 1990;9:1447–1454. 2281232
24. Parpia S, Thabane L, Julian JA, Whelan TJ, Levine MN. Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study. BMC Med Res Methodol. 2013;13:44. doi: 10.1186/1471-2288-13-44 23517401
25. Tunes da SG, Logan BR, Klein JP. Methods for equivalence and noninferiority testing. Biol Blood Marrow Transplant. 2009;15(1 Suppl):120–127. doi: 10.1016/j.bbmt.2008.10.004 19147090
26. Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother. 2002;46:778–782. 11850261
27. Krishna S, Nagaraja NV, Planche T, Agbenyega T, Bedo-Addo G, Ansong D, et al. Population pharmacokinetics of intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother. 2001;45:1803–1809. 11353629
28. Van TD, Dieye B, Valim C, Daniels RF, Sene PD, Lukens AK, et al. Changes in drug sensitivity and anti-malarial drug resistance mutations over time among Plasmodium falciparum parasites in Senegal. Malar J. 2013;12:441. doi: 10.1186/1475-2875-12-441 24314037
29. Bustamante C, Folarin OA, Gbotosho GO, Batista CN, Mesquita EA, Brindeiro RM, et al. In vitro-reduced susceptibility to artemether in P. falciparum and its association with polymorphisms on transporter genes. J Infect Dis. 2012;206:324–332. doi: 10.1093/infdis/jis359 22615315
30. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364:438–447. 15288742
31. Hendriksen IC, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge MM, et al. Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen. Clin Pharmacol Ther. 2013;93:443–450. doi: 10.1038/clpt.2013.26 23511715
32. Jaureguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, et al. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood. 2014;124:167–175. doi: 10.1182/blood-2014-02-555953 24859359
33. Bethell D, Se Y, Lon C, Socheat D, Saunders D, Teja-Isavadharm P, et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis. 2010;51:e105–e114. doi: 10.1086/657402 21070142
34. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647–1657. doi: 10.1016/S0140-6736(10)61924-1 21062666
35. Helbok R, Kendjo E, Issifou S, Lackner P, Newton CR, Kombila M, et al. The Lambarene Organ Dysfunction Score (LODS) is a simple clinical predictor of fatal malaria in African children. J Infect Dis. 2009;200:1834–1841. doi: 10.1086/648409 19911989
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2016 Číslo 1
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial
- Sharing Individual Participant Data (IPD) within the Context of the Trial Reporting System (TRS)
- Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003–2012
- Between Openness and Privacy in Genomics